|hello doctor, i am confused with your comment in the link, please help
Jan 6, 2012
hello doctor, please check the link, you said something in the media that i could not understand. earlier initiation of treatment is not going to give any benefit regarding longevity? the link: http://choicehivaids.org/other-news/151-starting-hiv-drugs-earlier-may-delay-aids-but-not-death regards.
| Response from Dr. Henry
That particular study did not clearly show a death benefit in persons with the highest CD4 count (> 500) though other health benfits (prevention of AIDS or improvement in health parameters) can occur. There is also likely a public health benefit to starting HIV treatment at high CD4 counts (preventing transmission) so the issue of starting HIV treatment in persons with high/near normal CD4 counts involves more than a short term death benefit. The START Study is looking at the clinical benefits of starting HIV treatment for persons with CD4 counts > 500 (randomized clinical trial) in an effort to more clearly define the clinical benefit of antiretroviral therapy for that patient population. KH
Get Email Notifications When This Forum Updates or Subscribe With RSS
- Is Hiv Spotted In A Physical Blood Test?
- Will I Be Okay Having Protected Sex With Hpv?
- Will A Baby Have Herpes If The Mother Has It?
- What If You Took Medicine For Chlamydia And I Still Have Symptoms What Does That Mean?
- What Do Genital Herpes Look Like When They First Start?
- What Age Group Is Most Affected By Chlamydia?
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.